NAUT — Nautilus Biotechnology Inc
NASDAQ · Healthcare · Biotechnology
$0.93
-$0.05 (-4.72%)
Nautilus Biotechnology Inc (NAUT) is a biotechnology company listed on NASDAQ. It is led by Sujal M. Patel, based in 2701 Eastlake Avenue East, Seattle, WA, United States, 98102, with about 134 employees. Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers reagent kits, which include sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Net income was -$13.6M. NAUT currently screens at market cap $103.4M.
Use this NAUT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NAUT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NAUT SEC filings page. Lician reads the product cache first so this HTML stays unique to Nautilus Biotechnology Inc even when a live quote feed is slow.
About Nautilus Biotechnology Inc
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers reagent kits, which include sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
NAUT Key Statistics
Market Cap
$103.44M
Volume
472,955
Previous Close
$0.88
Day Range
$0.86 – $0.92
EPS
-$0.56
Revenue
$0.00
Net Income
-$70.78M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
134
NAUT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$70.78M | -$63.67M | -$57.92M | -$50.31M |
| EPS (Diluted) | -$0.56 | -$0.51 | -$0.46 | -$0.60 |
Total Assets
$242.74M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$27.65M
Operating Cash Flow
-$59.15M
Free Cash Flow
$0.00
Nautilus Biotechnology Inc Company Information
- Co-Founder, CEO, President, Secretary & Director
- Sujal M. Patel
- Headquarters
- 2701 Eastlake Avenue East, Seattle, WA, United States, 98102
- Website
- www.nautilus.bio
- Phone
- 206 333 2001
- IPO / Founded
- 2021-06-10
- Sector
- Healthcare
- Industry
- Biotechnology